Measles and Poliomyelitis

Editor's introduction Measles and poliomyelitis: vaccines, immunization, and control.- I. Measles Global Control.- 1. Challenges for the global control of measles in the 1990's.- 2. The experience with measles in the United States.- 3. Mass vaccination programme aimed at eradication of measles in Sweden.- 4. Identification of high risk groups for measles immunization.- 5. Is measles eradicable?.- 6. Safety of measles vaccines.- 7. Measles vaccines-one versus two doses: why and when.- 8. Cost-benefit analysis of a second dose measles inoculation of children.- 9. High-titer measles virus vaccines: protection evaluation.- 10. Recent approaches in the development of measles vaccines.- 11. Molecular biological basis of measles virus strain differences.- 12. Measles virus antigenic variations and the role of individual antigens in immunization.- 13. Cell-mediated immune response to measles virus.- II. Towards Poliomyelitis Eradication.- 14. Lessons from poliovirus control: strategies for eradication.- 15. Eradication of poliomyelitis: countdown or slowdown.- 16. The potential for poliovirus eradication.- 17. Poliovirus immunization situation in China.- 18. Epidemiologic and laboratory classification systems for paralytic poliomyelitis cases.- 19. Monitoring of the environment as a means of poliovirus surveillance.- 20. Criteria for the certification of poliomyelitis eradication.- 21. Poliovirus vaccine formulations.- 22. Inactivated and live attenuated poliovirus vaccines: mucosal immunity.- 23. Immunogenicity of poliovirus vaccines with special reference to the choice between oral and inactivated vaccines in developing countries.- 24. Optimal schedule for the administration of oral poliovirus vaccine.- 25. Poliovirus combined immunization with inactivated and liveattenuated vaccines.- 26. Antigenicity and immunogenicity of inactivated poliovirus vaccine in combined vaccine trials.- 27. Studies aiming at improvement of inactivated poliovirus vaccine preparations.- 28. Development of candidates for new types 2 and 3 oral poliovirus recombinant vaccines.- 29. Intratypic differentiation of polioviruses.- 30. Natural evolution of oral vaccine poliovirus strains.- 31. Stability of attenuated poliovirus strain genotypes in the human intestinal tract.